Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility

Overview of attention for article published in Therapeutics and Clinical Risk Management, February 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

So far, Altmetric has seen 3 news stories from 1 outlets.

By David Bautz, PhD OTC:OPNT Financial Update On March 16, 2017, Opiant Pharmaceuticals, Inc.

By David Bautz, PhD NASDAQ:MNOV MN-166 in ALSThere have been a number of recent announcements regarding MN-166 (ibudilast) in…

By David Bautz, PhD NASDAQ:MNOV MN-166 Update MediciNova ( MNOV ) is developing MN-166 (ibudilast) for the treatment of primary…